Pyrotinib Plus Fulvestrant in Patients HR+/HER2+ Metastatic Breast Cancer : a Prospective, Single-arm, Single-center Study
Latest Information Update: 27 Sep 2023
At a glance
- Drugs Fulvestrant (Primary) ; Pyrotinib (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
Most Recent Events
- 26 Jul 2019 New trial record